Metabolic syndrome and inflammatory biomarkers: A community-based cross-sectional study at the Framingham Heart Study

Diabetology and Metabolic Syndrome

Volumn 4, Issue 1, 2012, Pages

  Dallmeier, Dhayana ^a,b   Larson, Martin G ^b,c,e   Vasan, Ramachandran S ^a,b   Keaney, John F ^f   Fontes, Joao D ^a,b   Meigs, James B ^d   Fox, Caroline S ^b,g   Benjamin, Emelia J ^a,b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Boston University   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Body mass index; Inflammatory biomarkers; Insulin resistance; Metabolic syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPROTEGERIN; PADGEM PROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; HEALTH PROGRAM; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; SEX RATIO; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84862336967     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-4-28     Document Type: Article

References (29)

1. Inflammation and metabolic disorders. Hotamisligil GS, Nature 2006 444 7121 860 867 10.1038/nature05485 17167474 (Pubitemid 46024993)
2. Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Pischon T, Hu FB, Rexrode KM, Girman CJ, Manson JE, Rimm EB, Atherosclerosis 2008 197 1 392 399 10.1016/j.atherosclerosis.2007.06.022 17681508 (Pubitemid 351273261)
3. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Haffner SM, Am J Cardiol 2006 97 2 11 13
4. Cardiovascular death and the metabolic syndrome: role of adiposity-signaling hormones and inflammatory markers. Langenberg C, Bergstrom J, Scheidt-Nave C, Pfeilschifter J, Barrett-Connor E, Diabetes Care 2006 29 6 1363 1369 10.2337/dc05-2385 16732022 (Pubitemid 44125936)
5. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, Circulation 2004 109 3 433 438 10.1161/01.CIR.0000111245.75752.C6 14744958 (Pubitemid 38133916)
6. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L, Diabetes Care 2001 24 4 683 689 10.2337/diacare.24.4.683 11315831 (Pubitemid 32893993)
7. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Alexander CM, Landsman PB, Teutsch SM, Haffner SM, Diabetes 2003 52 5 1210 1214 10.2337/diabetes.52.5.1210 12716754 (Pubitemid 36523358)
8. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT, JAMA 2002 288 21 2709 2716 10.1001/jama.288.21.2709 12460094 (Pubitemid 35403784)
9. Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Diabetes Res Clin Pract 2007 75 2 235 240 10.1016/j.diabres. 2006.06.019 16872712 (Pubitemid 44894605)
10. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Jacobs M, van Greevenbroek MM, van der Kallen CJ, Ferreira I, Blaak EE, Feskens EJ, Jansen EH, Schalkwijk CG, Stehouwer CD, Eur J Clin Invest 2009 39 6 437 444 10.1111/j.1365-2362.2009.02129.x 19397692
11. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F, Circulation 2003 107 3 499 511 10.1161/01.CIR.0000052939.59093.45 12551878 (Pubitemid 36158056)
12. The association between circulating inflammatory markers and metabolic syndrome in Korean rural adults. Ryu SY, Kim KS, Park J, Kang MG, Han MA, J Prev Med Public Health 2008 41 6 413 418 10.3961/jpmph.2008.41.6.413 19037171
13. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Simmons RK, Alberti KG, Gale EA, Colagiuri S, Tuomilehto J, Qiao Q, Ramachandran A, Tajima N, Brajkovich Mirchov I, Ben-Nakhi A, Reaven G, Hama Sambo B, Mendis S, Roglic G, Diabetologia 2010 53 4 600 605 10.1007/s00125-009-1620-4 20012011
14. Prevalence and trends in obesity among US adults, 1999-2000. Flegal KM, Carroll MD, Ogden CL, Johnson CL, JAMA 2002 288 14 1723 1727 10.1001/jama.288.14.1723 12365955
15. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. Ford ES, Giles WH, Dietz WH, JAMA 2002 287 3 356 359 10.1001/jama.287.3.356 11790215 (Pubitemid 34251969)
16. Inflammatory markers in relation to insulin resistance and the metabolic syndrome. Ingelsson E, Hulthe J, Lind L, Eur J Clin Invest 2008 38 7 502 509 10.1111/j.1365-2362.2008.01962.x 18489581 (Pubitemid 351832033)
17. The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Bayturan O, Tuzcu EM, Lavoie A, Hu T, Wolski K, Schoenhagen P, Kapadia S, Nissen SE, Nicholls SJ, Arch Intern Med 2010 170 5 478 484 10.1001/archinternmed.2009.551 20212186
18. Risk associated with the metabolic syndrome versus the sum of its individual components. Sundstrom J, Vallhagen E, Riserus U, Byberg L, Zethelius B, Berne C, Lind L, Ingelsson E, Diabetes Care 2006 29 7 1673 1674 10.2337/dc06-0664 16801601 (Pubitemid 44127603)
19. Association between metabolic syndrome or its components and asymptomatic cardiovascular disease in the RIVANA-study. Guembe MJ, Toledo E, Barba J, Martinez-Vila E, Gonzalez-Diego P, Irimia P, Diez J, Vines JJ, Atherosclerosis 2010 211 2 612 617 10.1016/j.atherosclerosis.2010.03.004 20362993
20. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Schnabel R, Larson MG, Dupuis J, Lunetta KL, Lipinska I, Meigs JB, Yin X, Rong J, Vita JA, Newton-Cheh C, Levy D, Keaney JF, Vasan RS, Mitchell GF, Benjamin EJ, Hypertension 2008 51 6 1651 1657 10.1161/HYPERTENSIONAHA.107.105668 18426996
21. The relation of genetic and environmental factors to systemic inflammatory biomarker concentrations. Schnabel RB, Lunetta KL, Larson MG, Dupuis J, Lipinska I, Rong J, Chen MH, Zhao Z, Yamamoto JF, Meigs JB, Nicaud V, Perret C, Zeller T, Blankenberg S, Tiret L, Keaney JF, Vasan RS, Benjamin EJ, Circ Cardiovasc Genet 2009 2 3 229 237 10.1161/CIRCGENETICS.108.804245 20031590
22. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, D'Agostino RB, J Clin Endocrinol Metab 2006 91 8 2906 2912 10.1210/jc.2006-0594 16735483 (Pubitemid 44271734)
23. Epidemiological approaches to heart disease: the Framingham Study. Dawber TR, Meadors GF, Moore FE, Am J Public Health Nations Health 1951 41 3 279 281 10.2105/AJPH.41.3.279 14819398
24. Visceral and Subcutaneous Adipose Tissue Volumes Are Cross-Sectionally Related to Markers of Inflammation and Oxidative Stress. The Framingham Heart Study. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, Keaney JF, Meigs JB, Lipinska I, Kathiresan S, Murabito JM, O'Donnell CJ, Benjamin EJ, Fox CS, Circulation 2007 116 11 1234 1241 10.1161/CIRCULATIONAHA. 107.710509 17709633 (Pubitemid 47517534)
25. The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C, Atherosclerosis 2005 183 2 308 315 10.1016/j.atherosclerosis.2005.03.010 16285994 (Pubitemid 41579282)
26. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW, Arterioscler Thromb Vasc Biol 1999 19 4 972 978 10.1161/01.ATV.19.4.972 10195925 (Pubitemid 29177345)
27. The association of tumor necrosis factor alpha receptor 2 and tumor necrosis factor alpha with insulin resistance and the influence of adipose tissue biomarkers in humans. Hivert MF, Sullivan LM, Shrader P, Fox CS, Nathan DM, D'Agostino RB, Wilson PW, Benjamin EJ, Meigs JB, Metabolism 2010 59 4 540 546 10.1016/j.metabol.2009.08.017 19846171
28. P-Selection as a new gender associated biomarker in patients with metabolic syndrome. Straface E, Gambardella L, Canali E, Metere A, Gabrielli N, Arcieri R, Mattatelli A, Lista P, Agati L, Malorni W, Int J Cardiol 2010 145 3 570 571 10.1016/j.ijcard.2010.05.043 20550976
29. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome-the Chennai Urban Rural Epidemiology Study. Gokulakrishnan K, Deepa R, Mohan V, Gross MD, Metabolism 2006 55 2 237 242 10.1016/j.metabol.2005.08.019 16423632 (Pubitemid 43098993)